Guoyang He

Dr. Guoyang He

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in Clinica Chimica Acta
Verified
Journal Article
Closed access
ZXZishan Xu
Zishan Xu
WLWei Li
Wei Li
XDXiangyang Dong
Xiangyang Dong
YCYingying Chen
Yingying Chen
DZDan Zhang
Dan Zhang
GHGuoyang He
Guoyang He

24 February 2023 in Cancer Science
Verified
Journal Article
Open access
GHGuoyang He
Guoyang He
WLWei Li
Wei Li
WZWenli Zhao
Wenli Zhao
HMHui Men
Hui Men
QCQingqing Chen
Qingqing Chen
LLli Liang
li Liang
Increasing evidence indicates that angiogenesis plays a pivotal role in tumor progression. Formin‐like 2 (FMNL2) is well‐known for promoting metastasis; however, the molecular mechanisms by which FMNL2 promotes angiogenesis in colorectal cancer (CRC) remain unclear. Here, we found that FMNL2 promotes angiogenesis and metastasis of CRC in vitro and in vivo. The GDB/FH3 domain of FMNL2 directly interacts with epidermal growth factor‐like protein 6 (EGFL6). Formin‐like 2 promotes EGFL6 paracrine signaling by exosomes to regulate angiogenesis in CRC. Cytoskeleton associated protein 4 (CKAP4) is a downstream target of EGFL6 and is involved in CRC angiogenesis. Epidermal growth factor‐like protein 6 binds to the N‐terminus of CKAP4 to promote the migration of HUVECs by activating the ERK/MMP pathway. These findings suggest that FMNL2 promotes the migration of HUVECs and enhances angiogenesis and tumorigenesis in CRC by regulating the EGFL6/CKAP4/ERK axis. Therefore, the EGFL6/CKAP4/ERK axis could be a candidate therapeutic target for CRC treatment.

24 March 2023 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JZJingyu Zhang
Jingyu Zhang
WLWei Li
Wei Li
WWWenxin Wang
Wenxin Wang
QCQingqing Chen
Qingqing Chen
ZXZishan Xu
Zishan Xu
GHGuoyang He
Guoyang He

31 December 2022 in Journal of Proteomics
Verified
Journal Article
Closed access
HZHuifang Zhu
Huifang Zhu
YLYongzhen Li
Yongzhen Li
JGJingyu Guo
Jingyu Guo
SFShuang Feng
Shuang Feng
HGHong Ge
Hong Ge
GHGuoyang He
Guoyang He

21 January 2024 in Genes
Verified
Journal Article
Open access
PDF file
WWWenxin Wang
Wenxin Wang
WLWei Li
Wei Li
DZDan Zhang
Dan Zhang
YMYongrun Mi
Yongrun Mi
JZJingyu Zhang
Jingyu Zhang
GHGuoyang He
Guoyang He
Objective: This study explores the potential causal association between proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors and tumor development using Mendelian randomization (MR) based on drug targets. Methods: Instrumental variables within ±100 kb of the PCSK9 gene locus, impacting low-density lipoprotein cholesterol (LDL-C), were utilized for MR analysis. Coronary heart disease (CHD) served as a positive control to validate the causal relationship between PCSK9 inhibitors and various cancers. We employed reverse MR to address the reverse causation concerns. Data from positive controls and tumors were sourced from OpenGWAS. Results: MR analysis suggested a negative causal relationship between PCSK9 inhibitors and both breast and lung cancers (95%CIBreast cancer 0.81~0.99, p = 2.25 × 10−2; 95%CILung cancer 0.65~0.94, p = 2.55 × 10−3). In contrast, a positive causal link was observed with gastric, hepatic, and oral pharyngeal cancers and cervical intraepithelial neoplasia (95%CIGastric cancer 1.14~1.75, p = 1.88 × 10−2; 95%CIHepatic cancer 1.46~2.53, p = 1.16 × 10−2; 95%CIOral cavity and pharyngeal cancer 4.49~6.33, p = 3.36 × 10−4; 95%CICarcinoma in situ of cervix uteri 4.56~7.12, p = 6.91 × 10−3), without heterogeneity or pleiotropy (p > 0.05). Sensitivity analyses confirmed these findings. The results of MR of drug targets suggested no causal relationship between PCSK9 inhibitors and bladder cancer, thyroid cancer, pancreatic cancer, colorectal cancer, malignant neoplasms of the kidney (except for renal pelvis tumors), malignant neoplasms of the brain, and malignant neoplasms of the esophagus (p > 0.05). Reverse MR helped mitigate reverse causation effects. Conclusions: The study indicates a divergent causal relationship of PCSK9 inhibitors with certain cancers. While negatively associated with breast and lung cancers, a positive causal association was observed with gastric, hepatic, oral cavity, and pharyngeal cancers and cervical carcinoma in situ. No causal links were found with bladder, thyroid, pancreatic, colorectal, certain kidney, brain, and esophageal cancers.

15 September 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
ZPZhenxiang Pu
Zhenxiang Pu
QLQian Li
Qian Li
CLChuanyin Lu
Chuanyin Lu
ZXZishan Xu
Zishan Xu
TZTaofei Zhou
Taofei Zhou
GHGuoyang He
Guoyang He